Cargando…
A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions
One of the routine clinical treatments to eliminate ischemic stroke thrombi is injecting a biochemical product into the patient’s bloodstream, which breaks down the thrombi’s fibrin fibers: intravenous or intravascular thrombolysis. However, this procedure is not without risk for the patient; the wo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444897/ https://www.ncbi.nlm.nih.gov/pubmed/37608073 http://dx.doi.org/10.1038/s41598-023-40973-1 |
_version_ | 1785094057163227136 |
---|---|
author | Petkantchin, Remy Rousseau, Alexandre Eker, Omer Zouaoui Boudjeltia, Karim Raynaud, Franck Chopard, Bastien |
author_facet | Petkantchin, Remy Rousseau, Alexandre Eker, Omer Zouaoui Boudjeltia, Karim Raynaud, Franck Chopard, Bastien |
author_sort | Petkantchin, Remy |
collection | PubMed |
description | One of the routine clinical treatments to eliminate ischemic stroke thrombi is injecting a biochemical product into the patient’s bloodstream, which breaks down the thrombi’s fibrin fibers: intravenous or intravascular thrombolysis. However, this procedure is not without risk for the patient; the worst circumstances can cause a brain hemorrhage or embolism that can be fatal. Improvement in patient management drastically reduced these risks, and patients who benefited from thrombolysis soon after the onset of the stroke have a significantly better 3-month prognosis, but treatment success is highly variable. The causes of this variability remain unclear, and it is likely that some fundamental aspects still require thorough investigations. For that reason, we conducted in vitro flow-driven fibrinolysis experiments to study pure fibrin thrombi breakdown in controlled conditions and observed that the lysis front evolved non-linearly in time. To understand these results, we developed an analytical 1D lysis model in which the thrombus is considered a porous medium. The lytic cascade is reduced to a second-order reaction involving fibrin and a surrogate pro-fibrinolytic agent. The model was able to reproduce the observed lysis evolution under the assumptions of constant fluid velocity and lysis occurring only at the front. For adding complexity, such as clot heterogeneity or complex flow conditions, we propose a 3-dimensional mesoscopic numerical model of blood flow and fibrinolysis, which validates the analytical model’s results. Such a numerical model could help us better understand the spatial evolution of the thrombi breakdown, extract the most relevant physiological parameters to lysis efficiency, and possibly explain the failure of the clinical treatment. These findings suggest that even though real-world fibrinolysis is a complex biological process, a simplified model can recover the main features of lysis evolution. |
format | Online Article Text |
id | pubmed-10444897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-104448972023-08-24 A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions Petkantchin, Remy Rousseau, Alexandre Eker, Omer Zouaoui Boudjeltia, Karim Raynaud, Franck Chopard, Bastien Sci Rep Article One of the routine clinical treatments to eliminate ischemic stroke thrombi is injecting a biochemical product into the patient’s bloodstream, which breaks down the thrombi’s fibrin fibers: intravenous or intravascular thrombolysis. However, this procedure is not without risk for the patient; the worst circumstances can cause a brain hemorrhage or embolism that can be fatal. Improvement in patient management drastically reduced these risks, and patients who benefited from thrombolysis soon after the onset of the stroke have a significantly better 3-month prognosis, but treatment success is highly variable. The causes of this variability remain unclear, and it is likely that some fundamental aspects still require thorough investigations. For that reason, we conducted in vitro flow-driven fibrinolysis experiments to study pure fibrin thrombi breakdown in controlled conditions and observed that the lysis front evolved non-linearly in time. To understand these results, we developed an analytical 1D lysis model in which the thrombus is considered a porous medium. The lytic cascade is reduced to a second-order reaction involving fibrin and a surrogate pro-fibrinolytic agent. The model was able to reproduce the observed lysis evolution under the assumptions of constant fluid velocity and lysis occurring only at the front. For adding complexity, such as clot heterogeneity or complex flow conditions, we propose a 3-dimensional mesoscopic numerical model of blood flow and fibrinolysis, which validates the analytical model’s results. Such a numerical model could help us better understand the spatial evolution of the thrombi breakdown, extract the most relevant physiological parameters to lysis efficiency, and possibly explain the failure of the clinical treatment. These findings suggest that even though real-world fibrinolysis is a complex biological process, a simplified model can recover the main features of lysis evolution. Nature Publishing Group UK 2023-08-22 /pmc/articles/PMC10444897/ /pubmed/37608073 http://dx.doi.org/10.1038/s41598-023-40973-1 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Petkantchin, Remy Rousseau, Alexandre Eker, Omer Zouaoui Boudjeltia, Karim Raynaud, Franck Chopard, Bastien A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions |
title | A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions |
title_full | A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions |
title_fullStr | A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions |
title_full_unstemmed | A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions |
title_short | A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions |
title_sort | simplified mesoscale 3d model for characterizing fibrinolysis under flow conditions |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444897/ https://www.ncbi.nlm.nih.gov/pubmed/37608073 http://dx.doi.org/10.1038/s41598-023-40973-1 |
work_keys_str_mv | AT petkantchinremy asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT rousseaualexandre asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT ekeromer asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT zouaouiboudjeltiakarim asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT raynaudfranck asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT chopardbastien asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT petkantchinremy simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT rousseaualexandre simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT ekeromer simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT zouaouiboudjeltiakarim simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT raynaudfranck simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT chopardbastien simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions AT simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions |